Stifel 2026 Healthcare Conference 2026
Logotype for Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals (RYTM) Stifel 2026 Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Rhythm Pharmaceuticals Inc

Stifel 2026 Healthcare Conference 2026 summary

11 Nov, 2026

U.S. AHO launch

  • More than 700 start forms and ~500 unique HCP prescribers reported after approval in March; 25% of HCPs were repeat prescribers.

  • Excluding clinical trial patients, the Q2 pace continued through October; management expects the pace to continue, supported by broad reach across targeted endocrinologists.

  • Endocrinology capacity and patients’ regularly scheduled visits for hormone replacement can limit how quickly diagnosed patients move to treatment.

  • Payer adoption of positive coverage policies has been faster than for BBS, supported by existing drug availability, stronger data and the severity of the underlying injury.

  • Through 2027, priorities include broadening patients on therapy, increasing HCP reach and repeat prescribing, and supporting continued revenue growth.

Japan and other ex-U.S. markets

  • AHO was approved in Japan in October; more than 1,000 patients have been identified and treatment has begun.

  • First-year Japanese uptake is expected to be modest because prescriptions must be renewed every two weeks for the first 12 months; management expects launch momentum to build after the restriction lifts.

  • Japan AHO prevalence is estimated at 5,000–8,000 patients, versus ~10,000 in the U.S.; management cited higher craniopharyngioma incidence, expected higher diagnosis and supportive market conditions.

  • Germany reimbursement exception is expected in Q1, followed by launch; France launch is anticipated in 2027 after supplemental price negotiation, while Italy and U.K. access efforts are also progressing.

  • Management expects a higher ex-U.S. AHO contribution in 2027 as launches take hold, with more specific timelines to come early in the year.

Bivamelagon and Prader-Willi syndrome

  • A licensing amendment commits $350 million over four years to reduce bivamelagon royalties from 5%–7% to 1%, removing an economic disincentive to development.

  • Bivamelagon is planned to lead next-generation PWS development; management hopes to meet the FDA in 2027 and start a hyperphagia-focused study that year.

  • The proposed PWS Phase III study is six months, placebo-controlled, with HQ-CT as the primary endpoint; clinically meaningful hyperphagia measured by HQ-CT is expected to be an entry criterion.

  • In Phase II, all six adults with clinically meaningful hyperphagia had HQ-CT reductions through six months, as did three of five children; management expects placebo effects to normalize by six months.

  • Bivamelagon was selected ahead of RM-718 based on clinical supply readiness, KOL feedback favoring daily routine administration, and the revised royalty economics.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Rhythm Pharmaceuticals